21st Century Cures Act Seen as a Big Boost to Big Pharma

The House approved it by a 392 to 26 vote.

Photo courtesy of Pexels

The 21st Century Cures Act, aimed at expediting the research and use of new medicines, passed the House of Representatives by a 392 to 26 vote Monday. The Cures Act, which is expected to pass the Senate as well, remains controversial despite its surprising bipartisan support.

Drug companies and medical device manufacturers are seen as the big winners here. Major opponents, such as Senator Elizabeth Warren, raise concerns about the power of the big pharmaceutical companies that lobbied heavily for the bill. “Scientists who invent new cures should be celebrated, along with the companies that support then,” she said in a recent floor speech. “But let me be perfectly clear. While the drug industry may get a seat at the the table, they do not own the table.”

The Cures Act would give $1 billion in state grants to address the opioid crisis and provide $4.8 billion over 10 years to fund research by the National Institutes of Health. But it also cuts $3.5 billion from the Prevention and Public Health Fund — a fund established under Obamacare to address chronic illnesses and potentially preventable diseases such as diabetes and Alzheimer’s.

Originally published at journal.thriveglobal.com

Share your comments below. Please read our commenting guidelines before posting. If you have a concern about a comment, report it here.

You might also like...


You Can Rescue Medical Breakthroughs from the Valley of Death

by Kevin Leland

Ending AIDS: Progress and Peril on This World AIDS Day 2016

by Susan Blumenthal, MD, MPA

Chris Geib of The National Pediatric Cancer Foundation: “Give back and get involved!”

by Ben Ari
We use cookies on our site to give you the best experience possible. By continuing to browse the site, you agree to this use. For more information on how we use cookies, see our Privacy Policy.